Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer

Okayama Lung Cancer Study Group experience

Katsuyuki Hotta, Katsuyuki Kiura, Nagio Takigawa, Etsuji Suzuki, Hiroshige Yoshioka, Toshiaki Okada, Daizo Kishino, Hiroshi Ueoka, Koji Inoue, Masahiro Tabata, Mitsune Tanimoto

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The relationship between poor performance status (PS) and toxicity during chemotherapy is controversial. We examined this for erlotinib monotherapy in non-small cell lung cancer (NSCLC) patients. Patients and methods: Toxicity during the first month of therapy was recorded in 209 patients receiving erlotinib for NSCLC, and its association with PS was assessed. Results: Of 209 patients, 52, 115, 30 and 12 had a PS of 0, 1, 2 and 3-4, respectively. Treatment was discontinued in 26% of patients within 1 month, with a higher rate in poorer PS patients (17%, 25%, 37% and 42%). Discontinuation was predominantly due to disease progression, rather than adverse events, in both the whole cohort (82% vs. 18%) and the poorest PS subgroup (100% vs. 0%). Three, two, and four patients with a PS of 1, 2 and 3-4, respectively, died within 1 month; all six deaths of PS 2-4 patients were attributed to disease progression. Treatment interruption and dose reduction rates were similar among the subgroups. The principal adverse event was skin rash, with identical incidence in all PS subgroups. Conclusions: Poor PS is unlikely to increase the risk for toxicity during erlotinib monotherapy, but was related to low compliance, probably because of disease progression rather than treatment-related toxicity.

Original languageEnglish
Pages (from-to)308-312
Number of pages5
JournalLung Cancer
Volume70
Issue number3
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Disease Progression
Erlotinib Hydrochloride
Therapeutics
Exanthema
Compliance
Drug Therapy
Incidence

Keywords

  • Erlotinib
  • Lung cancer
  • Performance status

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer : Okayama Lung Cancer Study Group experience. / Hotta, Katsuyuki; Kiura, Katsuyuki; Takigawa, Nagio; Suzuki, Etsuji; Yoshioka, Hiroshige; Okada, Toshiaki; Kishino, Daizo; Ueoka, Hiroshi; Inoue, Koji; Tabata, Masahiro; Tanimoto, Mitsune.

In: Lung Cancer, Vol. 70, No. 3, 12.2010, p. 308-312.

Research output: Contribution to journalArticle

@article{c10a89ce0359483b90c033341bc25e8a,
title = "Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience",
abstract = "Background: The relationship between poor performance status (PS) and toxicity during chemotherapy is controversial. We examined this for erlotinib monotherapy in non-small cell lung cancer (NSCLC) patients. Patients and methods: Toxicity during the first month of therapy was recorded in 209 patients receiving erlotinib for NSCLC, and its association with PS was assessed. Results: Of 209 patients, 52, 115, 30 and 12 had a PS of 0, 1, 2 and 3-4, respectively. Treatment was discontinued in 26{\%} of patients within 1 month, with a higher rate in poorer PS patients (17{\%}, 25{\%}, 37{\%} and 42{\%}). Discontinuation was predominantly due to disease progression, rather than adverse events, in both the whole cohort (82{\%} vs. 18{\%}) and the poorest PS subgroup (100{\%} vs. 0{\%}). Three, two, and four patients with a PS of 1, 2 and 3-4, respectively, died within 1 month; all six deaths of PS 2-4 patients were attributed to disease progression. Treatment interruption and dose reduction rates were similar among the subgroups. The principal adverse event was skin rash, with identical incidence in all PS subgroups. Conclusions: Poor PS is unlikely to increase the risk for toxicity during erlotinib monotherapy, but was related to low compliance, probably because of disease progression rather than treatment-related toxicity.",
keywords = "Erlotinib, Lung cancer, Performance status",
author = "Katsuyuki Hotta and Katsuyuki Kiura and Nagio Takigawa and Etsuji Suzuki and Hiroshige Yoshioka and Toshiaki Okada and Daizo Kishino and Hiroshi Ueoka and Koji Inoue and Masahiro Tabata and Mitsune Tanimoto",
year = "2010",
month = "12",
doi = "10.1016/j.lungcan.2010.03.008",
language = "English",
volume = "70",
pages = "308--312",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer

T2 - Okayama Lung Cancer Study Group experience

AU - Hotta, Katsuyuki

AU - Kiura, Katsuyuki

AU - Takigawa, Nagio

AU - Suzuki, Etsuji

AU - Yoshioka, Hiroshige

AU - Okada, Toshiaki

AU - Kishino, Daizo

AU - Ueoka, Hiroshi

AU - Inoue, Koji

AU - Tabata, Masahiro

AU - Tanimoto, Mitsune

PY - 2010/12

Y1 - 2010/12

N2 - Background: The relationship between poor performance status (PS) and toxicity during chemotherapy is controversial. We examined this for erlotinib monotherapy in non-small cell lung cancer (NSCLC) patients. Patients and methods: Toxicity during the first month of therapy was recorded in 209 patients receiving erlotinib for NSCLC, and its association with PS was assessed. Results: Of 209 patients, 52, 115, 30 and 12 had a PS of 0, 1, 2 and 3-4, respectively. Treatment was discontinued in 26% of patients within 1 month, with a higher rate in poorer PS patients (17%, 25%, 37% and 42%). Discontinuation was predominantly due to disease progression, rather than adverse events, in both the whole cohort (82% vs. 18%) and the poorest PS subgroup (100% vs. 0%). Three, two, and four patients with a PS of 1, 2 and 3-4, respectively, died within 1 month; all six deaths of PS 2-4 patients were attributed to disease progression. Treatment interruption and dose reduction rates were similar among the subgroups. The principal adverse event was skin rash, with identical incidence in all PS subgroups. Conclusions: Poor PS is unlikely to increase the risk for toxicity during erlotinib monotherapy, but was related to low compliance, probably because of disease progression rather than treatment-related toxicity.

AB - Background: The relationship between poor performance status (PS) and toxicity during chemotherapy is controversial. We examined this for erlotinib monotherapy in non-small cell lung cancer (NSCLC) patients. Patients and methods: Toxicity during the first month of therapy was recorded in 209 patients receiving erlotinib for NSCLC, and its association with PS was assessed. Results: Of 209 patients, 52, 115, 30 and 12 had a PS of 0, 1, 2 and 3-4, respectively. Treatment was discontinued in 26% of patients within 1 month, with a higher rate in poorer PS patients (17%, 25%, 37% and 42%). Discontinuation was predominantly due to disease progression, rather than adverse events, in both the whole cohort (82% vs. 18%) and the poorest PS subgroup (100% vs. 0%). Three, two, and four patients with a PS of 1, 2 and 3-4, respectively, died within 1 month; all six deaths of PS 2-4 patients were attributed to disease progression. Treatment interruption and dose reduction rates were similar among the subgroups. The principal adverse event was skin rash, with identical incidence in all PS subgroups. Conclusions: Poor PS is unlikely to increase the risk for toxicity during erlotinib monotherapy, but was related to low compliance, probably because of disease progression rather than treatment-related toxicity.

KW - Erlotinib

KW - Lung cancer

KW - Performance status

UR - http://www.scopus.com/inward/record.url?scp=78049399723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049399723&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2010.03.008

DO - 10.1016/j.lungcan.2010.03.008

M3 - Article

VL - 70

SP - 308

EP - 312

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -